Donor substance abuse and heart transplantation outcomes

Sabra, Mohammad; Ilonze, Onyedika J.; Rao, Roopa A.; Saleem, Kashif; Guglin, Maya

doi:10.1007/s10741-022-10241-x

Cited by 1 publication

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…70 Some data suggest that opioid or cocaine used by the donor does not affect post-heart transplant outcomes, although information is limited. 71 All in all, additional studies with larger samples and longer follow up are awaited to better determine the safety of heart transplant from HCV NAT+ to uninfected recipients, particularly in the long-term.…”

Section: Direct-acting Antiviral Combinationmentioning

confidence: 99%

“…Last, substance abuse is often associated with HCV‐viremic donors, and its effects on heart transplant outcomes are unknown, as those donors were historically avoided, particularly when they used stimulants and other noradrenergic agents 70 . Some data suggest that opioid or cocaine used by the donor does not affect post‐heart transplant outcomes, although information is limited 71 . All in all, additional studies with larger samples and longer follow up are awaited to better determine the safety of heart transplant from HCV NAT+ to uninfected recipients, particularly in the long‐term.…”

Section: Mismatch Hcv Nat D+/r– Heart Transplantationmentioning

confidence: 99%

See 1 more Smart Citation

Hepatitis C and heart transplantation: An update

Nunez,

Kelkar

2023

Clinical Transplantation

View full text Add to dashboard Cite

There are limited data regarding heart transplantation in the setting of hepatitis C virus (HCV) infection in either recipients or donors, as the practice was infrequent, given concerns of worse post‐transplant outcomes. This changed dramatically after the development of highly effective HCV therapies, namely direct‐acting antivirals (DAAs). Additionally, nucleic acid testing currently in use establishes more precisely the risk of HCV transmission from donors. As a result, chronic HCV infection in itself is no longer a barrier for heart transplant candidates, and the use of HCV‐positive organs for HCV‐infected and non‐infected transplant candidates has increased dramatically. A review of the literature revealed that in the pre‐DAA era, HCV seropositive heart transplant patients had a higher mortality than their seronegative counterparts. However, short‐term data suggest that the differences in survival have been erased in the DAA era. Heart transplantation from HCV‐viremic donors to HCV‐uninfected recipients has become increasingly common as the number of deceased donors with HCV viremia has increased over the past years. Preliminary outcome reports are very encouraging, although further data are needed with regard to long‐term safety. New information continues to be incorporated to optimize protocols that guide this practice.

show abstract

Section: Direct-acting Antiviral Combinationmentioning

confidence: 99%

Section: Mismatch Hcv Nat D+/r– Heart Transplantationmentioning

confidence: 99%